申请人:Follmann Markus
公开号:US08378092B2
公开(公告)日:2013-02-19
The present invention relates to compounds of the formula I,
wherein R1; R2; R3; R4; R5, R13, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
本发明涉及公式I的化合物,其中R1;R2;R3;R4;R5,R13,R16,X和M具有所述权利要求中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用,例如,适用于治疗和预防心血管疾病,如血栓栓塞性疾病或再狭窄。它们是血凝酶因子Xa(FXa)和凝血酶的可逆抑制剂,通常可用于存在因子Xa和/或凝血酶不良活性或预防其发生的情况,或用于治疗或预防需要抑制因子Xa和凝血酶的情况。本发明还涉及制备公式I化合物的方法,它们的用途,特别是作为药物中的活性成分,以及包含它们的制药制剂。